Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.72 |
| ▸ | MAPT | P10636 | 6/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.72 |
| ▸ | GAA | P10253 | 3/20 | 0.72 |
| ▸ | RAD52 | P43351 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | CACNA2D1 | P54289 | 7/20 | 0.47 |
| ▸ | ESR1 | P03372 | 3/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8359537 | 0.84 | KDM4E (1.00) | KDM4EMAPTALDH1A1GAARAD52 | |
| SCHEMBL5001196 | 0.83 | MEN1 (0.63) | KDM4EMAPTALDH1A1GAARAD52 | |
| SCHEMBL8361036 | 0.81 | KDM4E (0.55) | KDM4EMAPTALDH1A1GAARAD52 | |
| SCHEMBL5008011 | 0.78 | KDM4E (0.71) | KDM4EMAPTALDH1A1GAARAD52 | |
| SCHEMBL20213714 | 0.76 | MEN1 (0.62) | KDM4EMAPTALDH1A1GAARAD52 | |
| SCHEMBL8361380 | 0.76 | KDM4E (1.00) | KDM4EMAPTALDH1A1GAARAD52 | |
| SCHEMBL13993249 | 0.74 | KDM4E (1.00) | KDM4EMAPTALDH1A1GAARAD52 | |
| SCHEMBL5001008 | 0.73 | CACNA2D1 (0.64) | KDM4EMAPTALDH1A1GAARAD52 | |
| SCHEMBL5004947 | 0.72 | THRB (0.69) | MAPTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL31280737 | 0.72 | PKM (0.49) | KDM4EMAPTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465730-B2 | Treatment of neuropathic pain with 6H-pyrrolo[3,4-d]pyridazine compounds | MERCK & CO. INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465730-B2 | Treatment of neuropathic pain with 6H-pyrrolo[3,4-d]pyridazine compounds | MERCK & CO. INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465730-B2 | Treatment of neuropathic pain with 6H-pyrrolo[3,4-d]pyridazine compounds | MERCK & CO. INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-20060154929-A1 | Treatment of neuropathic pain with 6h-pyrrolo[3,4-d]pyridazine compounds | MERCK SHARP & DOHME CORP. | 2006-07-13 | — | — | US | disclosed |
| WO-2004006836-A2 | TREATMENT OF NEUROPATHIC PAIN WITH 6H-PYRROLO[3,4-D]PYRIDAZINE COMPOUNDS | MERCK & CO., INC. (US) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154929-A1 | Treatment of neuropathic pain with 6h-pyrrolo[3,4-d]pyridazine compounds | GRIN2C, CACNA1C, CACNG4 | KDM4E 1778/4885MAPT 455/4885ALDH1A1 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.